We recently reported that dysregulated c-Jun N-terminal kinases (JNK) activity causes defective cell cycle checkpoint control, inducing neoplastic transformation in a cellular ulcerative colitis (UC) model. In the quiescent chronic phase of UC, p-p54 JNK was down-regulated and p-p46 JNK was up-regulated. Both were up-regulated in the acute phase. Consequently, increased p21 WAF1 and γ-H2AX, two JNK-regulated proteins, induced cell cycle arrest. Their down-regulation led to checkpoint override, causing increased proliferation and undetected DNA damage in quiescent chronic phase, all characteristics of tumorigenesis. We investigated expression of p-JNK2, p-JNK1-3, p21 WAF1 , γ-H2AX and Ki67 by immunohistochemistry in cases of quiescent UC (QUC), active UC (AUC), UC-dysplasia and UC-related colorectal carcinoma (UC-CRC). Comparison was made to normal healthy colorectal mucosa, sporadic adenoma and colorectal carcinoma (CRC), diverticulitis and Crohns disease (CD). We found p-JNK2 up-regulation in AUC and its early down-regulation in UC-CRC and CRC carcinogenesis. With downregulated p-JNK2, p21 WAF1 was also decreased. Ki67 was inversely expressed, showing increased proliferation early in UC-CRC and CRC carcinogenesis. p-JNK1-3 was increased in AUC and QUC. Less increased γ-H2AX in UC-CRC compared to CRC gave evidence that colitis-triggered inflammation masks DNA damage, thus contributing to neoplastic transformation. We hypothesize that JNK-dependent cell cycle arrest is important in AUC, while chronic inflammation causes dysregulated JNK activity in quiescent phase that may contribute to checkpoint override, promoting UC carcinogenesis. We suggest restoring p-JNK2 expression as a novel therapeutic strategy to early prevent the development of UC-related cancer.
Introduction
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that is characterized by cyclic colonic inflammation with active (AUC) and quiescent states (QUC). UC patients have an increased risk of developing UC-associated colorectal dysplasia and colorectal cancer (UC-CRC), which highlights the important link between inflammation and tumorigenesis (1) . Chronic inflammation activates several molecular pathways, including Wnt/ ß-catenin, Kras, p53, TGF and DNA mismatch repair proteins, thereby providing the driving force for the development of UC-CRC (2, 3) . The timing of the molecular events is often different between UC-CRC and sporadic colorectal cancer (CRC) (4), although p53 inactivation and subsequent p21 WAF1 down-regulation serve as pathogenic factors (5) (6) (7) (8) (9) . The c-Jun N-terminal kinases (JNK) are involved in inflammatory responses in the colon (10, 11) and are activated in murine models of colitis and in human patients (12) (13) (14) (15) . JNK are mitogen-activated protein kinases (MAPK) that are activated by several extracellular signals (16) (17) (18) , thus phosphorylating the AP1 transcription factor and proto-oncoprotein c-Jun (19) . Thus, c-Jun functions in cellular proliferation and tumorigenesis (11, 20) . Moreover, a crosstalk of JNK to Wnt signaling affects oncogenic transformation in mice by regulating intestinal stem cell function (11) . The JNK family is encoded by three genes, Jnk1, Jnk2 and Jnk3, each having two splicing variants (p46 and p54) (17, 21) . However, the exact role of the respective JNK isoforms in UC and UC-CRC need to be elucidated in more detail.
Defective cell cycle control is responsible for selective growth advantage in human cancers (22) (23) (24) (25) (26) . In order to develop novel therapeutic strategies, it is important to identify dysregulated proteins that switch the signaling pathways at the earliest stages of neoplastic transformation from controlled cell cycle arrest to uncontrolled proliferation (24) . For this purpose, we established a cellular UC in vitro model that mimics the in vivo conditions of UC by exposing human colonic epithelial cells (HCEC) to repeated cycles of hydrogen peroxide (H 2 O 2 ) with alternate regeneration phases (27, 28) . We found signs of neoplastic transformation and the associated molecular changes, such as the induction of ß-catenin, TCF4, c-Myc and c-Jun, as well as down-regulation of the tumor suppressor p21 WAF1 . To the best of our knowledge, we were the first to provide evidence that the JNK are activated in the acute phase, inducing JNK-dependent cell cycle arrests via up-regulated p21 WAF1 and γ-H2AX, while JNK activity was dysregulated in quiescent chronic phase associated with p21 WAF1 and γ-H2AX down-regulation ( Figure 1 ). Dysregulation of JNK activity was subjected to the down-regulation of p-p54 JNK and the up-regulation of p-p46 JNK, which resulted in an override of the DNA damage checkpoint control, increased IL6 release, enhanced proliferation and undetected DNA damage. Moreover, we hypothesized that p-p54 JNK acts as a novel tumor suppressor in the inflamed colon of UC patients (28) . In support of our hypothesis, p21 WAF1 and the DNA damage sensor γ-H2AX were suppressed through the dysregulation of JNK activity, resulting in both increased proliferation and undetected DNA damage (27, 28) . Importantly, both selective down-regulation of p-p54 JNK and selective up-regulation of p-p46 JNK seem to be a novel mechanism for p21 WAF1 and γ-H2AX down-regulation. In this study, we therefore asked whether this mechanism is also important in vivo. Unfortunately, there are no antibodies available for the p-p46 and p-p54 JNK variants for immunohistochemistry but there are for p-JNK2 and p-JNK1-3. As the Jnk1 gene mostly encodes p46 JNK and the Jnk2 gene mostly encodes p54 JNK (29) , we used antibodies for p-JNK2 and p-JNK1-3. As p-JNK3 is tissue-specific (expressed in the brain, heart and the testes), the p-JNK1-3 antibody should detect only p-JNK1/2 (19) . In addition, we also analyzed the expression of p21 WAF1 and γ-H2AX, which are JNK-regulated in the cellular colitis model (27, 28) , and the cellular proliferation marker Ki67 by immunohistochemistry.
Here, we hypothesize that dysregulation of JNK2 and JNK1-3 activity is involved in UC and sporadic colorectal carcinogenesis, and that p-JNK2 may function as a tumor suppressor in the inflamed and non-inflamed colon. In accord with our hypothesis, we present the first in vivo evidence of significant p-JNK2 down-regulation in QUC, UC-dysplasia, UC-CRC, sporadic adenoma and CRC.
Material and methods

Patients and tissue samples
In total, 286 specimens of colorectal biopsies or colon resections were analyzed. The first study group consisted of cases with unequivocal UC and was subdivided into active colitis (AUC; n = 42), quiescent colitis (QUC; n = 40), colitis-associated dysplasia (UC-dysplasia, n = 52) and colitis-associated colorectal carcinoma (UC-CRC; n = 30). In every case of dysplasia or carcinoma, there was endoscopic and/or pathologic evidence that the material originated from an area of the colon affected by UC. The second study group was composed of non-colitis cases and included uninflamed and dysplasia-free healthy controls (n = 40), sporadic colorectal adenomas (adenoma; n = 21), cases of sporadic colorectal carcinoma (CRC; n = 20), active Crohn's disease (CD; n = 21), and sigmoid diverticulitis (diverticulitis; n = 20).
Cases were recruited from the unselected continuous specimen material of the Department of Pathology, Otto-von-Guericke University, Magdeburg, and from the Academic Department of Pathology, St Mark's Hospital Harrow, UK. For this retrospective study on archival material, only anonymized data and tissues were used and participants gave no informed consent. Institute's Ethics committee approved the study (154/11). The withdrawal, processing and analysis of the tissue were performed in accordance with the guidelines of the local ethics research committee. Clinical and pathological characteristics of all cases are summarized in Table 1 down-regulated p-p54JNK. As a result, p21 WAF1 and γ-H2AX were down-regulated which leads to checkpoint override, and consequently to increased proliferation and undetected DNA damage. The proposed in vitro model also fits with the in vivo situation.
Immunohistochemistry
The tissue was formalin-fixed, dehydrated, paraffin-embedded and cut in 2 μm thick sections, which were dewaxed and rehydrated. The immunohistochemistry was done under standardized automated circumstances on the BenchMark® XT-or BenchMark® Ultra-Slide staining system (Ventana, Tucson, USA) in accordance with the manufacturer's specifications. The slides were incubated with the respective primary-antibody for 32 min at room temperature, after antigen retrieval was performed using Cell Conditioning Solution® (CC1, Ventana). For p-JNK2 immunohistochemistry, the polyclonal p-JNK2-antibody (Clone Thr 183) from Zytomed was used at a dilution of 1:1000. The specificity of this p-JNK2 antibody was ensured by immunoblotting (Supplementary Figure 1A , available at Carcinogenesis Online). Moreover, we used uninflamed colonic mucosa as positive and negative control, which contains epithelial cells with distinct nuclear staining for p-JNK2 as well as clearly negative epithelial cells (Supplementary Figure 1B , available at Carcinogenesis Online).
p-JNK1-3 immunohistochemistry was performed with a monoclonal antibody from Abcam (Clone EPR5693) at a 1:50 dilution. γ-H2AX immunohistochemistry was carried out with a polyclonal antibody from Novus Biologicals (Clone pSer139) used at a 1:750 dilution. For p21 WAF1 immunohistochemistry, the sections were incubated at a 1:20 dilution with a monoclonal-antibody (Clone EP147, Epitomics). Ki67 immunohistochemistry was accomplished with the monoclonal antibody Mib1 from DAKO at a 1:100 dilution. Visualization was performed with the ultraVIEW TM Universal DAB Detection Kit (Ventana). Slides were counterstained with Mayer's hematoxylin, dehydrated and cover slipped after embedding in mounting medium. For p-JNK2, p-JNK1-3, γ-H2AX and p21 WAF1 , normal colorectal mucosa was used as positive and negative control. For Ki67, normal tonsil served as positive and negative control.
Immunoblotting
To show the specificity of the p-JNK2 antibody used in the immunohistochemistry experiments, we performed immunoblotting of control normal colorectal mucosa using the p-JNK2 antibody as well as the ß-actin antibody as loading control (Supplementary Figure 1A , available at Carcinogenesis Online). The protein lysate of the tissues was prepared as follows. One hundred mg of tissue was homogenized in 1 ml lysis buffer with freshly added protease inhibitors using the VWR VDI12 homogenizer. After shaking for 2 h at 4°C, the lysates were centrifuged for 20 min at 12 000 rpm at 4°C. Determination of protein concentration of the collected supernatant was performed as described previously (30) . Supplemental Figure 1A , available at Carcinogenesis Online, shows a major band for p-JNK2, particularly for the p-p54 JNK isoforms, which clearly reflects high specificity of the p-JNK2 antibody.
Evaluation of protein staining
For all five proteins, only distinct nuclear staining of colonic epithelium was regarded positive: p-JNK2 and p-JNK1-3 sometimes showed a slight cytoplasmatic reaction, which in accordance with literature was not taken into account as it was inconsistent (14, 15, 31) . For p-JNK2, p-JNK1-3 and γ-H2AX immunohistochemistry in noncancerous cases, one representative crypt was chosen per patient and the percentage of positively stained cells was evaluated along the whole length of the crypt (Supplementary Figure 2 , available at Carcinogenesis Online). The chosen crypt had to be cut at whole length to evaluate all zones of the crypt. Furthermore, it had to be representative of the tested group. For example, in a case of active UC inflammation, alterations of the epithelium had to be seen. Therefore, the immunohistochemically stained slide was compared to its hematoxylin-eosin stained counter-slide. To examine the underlying pathology, any selected area had to be recognizable as representative to an experienced histopathologist and therefore, the evaluation of protein staining could not be blinded. In cancer cases, the percentage of positively stained tumor cells was quantified in three areas within the tumor that covered the surface, center and invasion front. When evaluating p21 WAF1 -and Ki67-immunohistochemistry, we divided the crypt into lower (Zone 1), middle (Zone 2) and upper third (Zone 3), the latter including the adjacent surface epithelium, to capture the different proliferative zones within the crypt, which affect p21 WAF1 -and Ki67-expression (Supplementary Figure 2B , available at Carcinogenesis Online). In non-cancerous cases, the percentage of cells was analyzed separately for every zone. In cancerous cases, the quantification of positive tumor cells was performed as described above. For p-JNK2, p-JNK1-3 and γ-H2AX no zonal distribution pattern could be found. The sections were assessed on a Nikon Eclipse E400 microscope in a 400-fold magnification. The photos were taken on the Nikon Eclipse Ni microscope with the Nikon DS-Fi2-Camera using NIS-Elements D 4.40.00 software in a 200-fold magnification. Figure 2 shows representative examples of p-JNK2, p-JNK1-3, p21 WAF1 , γ-H2AX and Ki67 immunohistochemistry.
Statistical analysis
The description of the clinical characteristics has the form x SD ± for continuous variables or n (%) for variables with discrete levels. A functional ANOVA (analysis of variance) with DUNNETT's correction for α was used for multiple comparisons to assess the relationship between mean values of immunohistochemical protein expression and study groups or clinicopathologic factors of the respective group. Additional univariate comparisons (subgroup analysis) between categories in special groups were carried out using the t-test (Welch test, Satterthwaite's approximation to compute the degrees of freedom) without α-adjustment. These results should be interpreted in an exploratory manner. Statistical analyses were made two-tailed with a critical probability of α = 0.05. All calculations were performed using the IBM® SPSS® Statistics Version 22. P value < 0.05 was considered statistically significant.
Results
p-JNK2 protein expression is increased in AUC, but decreased during colitis-associated and sporadic colorectal carcinogenesis
To assess p-JNK2 expression during colitis-associated carcinogenesis, we first examined and compared the nuclear immunostaining of p-JNK2 in control normal colorectal mucosa (n = 40), AUC (n = 42), QUC (n = 40), UC-dysplasia (n = 52), UC-CRC (n = 30), sporadic adenoma (n = 21), CRC (n = 20), CD (n = 21) and diverticulitis (n = 20), (Table 2; Figures 2A-C and 3A) . In accordance with the cellular colitis model published earlier (27) , we found significantly increased p-JNK2 expression in AUC compared to control normal colorectal mucosa (25.4 ± 4.2% versus 20.6 ± 4.4%, P < 0.001). Interestingly, in control normal colorectal mucosa and AUC, p-JNK2-positive cells were distributed evenly in the colonic crypt, while AUC showed a significantly increased number of stained cells (Figure 2A and B). In contrast, normal colon tissue had significantly higher p-JNK2 expression compared to QUC (16.8 ± 4.4%, P < 0.001), UC-dysplasia (13.6 ± 4.4%, P < 0.001), and UC-CRC (11.0 ± 4.8%, P < 0.001), confirming findings in vitro (27, 28) . There was a significant 8.6% reduction in p-JNK2 expression in QUC versus AUC (P < 0.0001). Expression of p-JNK2 in UC-dysplasia was significantly reduced compared to AUC (13.6 ± 4.4% versus 25.4 ± 4.2%, P < 0.0001), QUC (versus 16.8 ± 4.4%, P = 0.0008), and sporadic adenoma (versus 16.4 ± 4.5%, P = 0.015). In UC-CRC, p-JNK2 was significantly decreased compared to UC-dysplasia (11.0 ± 4.8% versus 13.6 ± 4.4%, P = 0.019). In addition, decreased p-JNK2 expression was found in sporadic adenomas (16.4 ± 4.5%, P = 0.003) and CRC (11.5 ± 2.7%, P < 0.001) compared to control normal colorectal mucosa. As shown for p-JNK2 up-regulation in AUC, p-JNK2 down-regulation in UC-CRC and CRC carcinogenesis showed a homogeneous expression pattern ( Figure 2C ). Next, we asked whether p-JNK2 up-regulation in AUC is directly linked to colitis-specific inflammation by investigating CD and diverticulitis specimens for p-JNK2 expression. In CD (14.9 ± 5.2, P < 0.001) and diverticulitis (9.2 ± 4.8%, P < 0.001), p-JNK2 was down-regulated rather than up-regulated compared to control normal colorectal mucosa (20.6 ± 4.4%), to AUC (25.4 ± 4.2%, P < 0.001) and to QUC (16.8 ± 4.4%, P < 0.001).
Overall, expression of p-JNK2 was specifically increased in AUC and not in CD and diverticulitis, while its down-regulation was linked not only to colitis-associated carcinogenesis but also to sporadic colorectal carcinogenesis. These data support the hypothesis that p-JNK2 has a tumor-suppressive function in the colitis-inflamed and non-inflamed colon.
p-JNK1-3 expression during colitis-associated and sporadic colorectal carcinogenesis
p-JNK1-3 showed a nuclear positivity within the colorectal epithelium with an evenly cryptal distribution similar to p-JNK-2 ( Figure 2D-F) . Expression of p-JNK1-3 was significantly increased in AUC (34.1 ± 9.3%, P < 0.001) and QUC (26.6 ± 6.9%, P < 0.001), but decreased in UC-CRC (11.5 ± 6.6%, P < 0.001), while there were marginal differences between UC-dysplasia (21.0 ± 8.7%, P = 0.833) and control normal colorectal mucosa (19.1 ± 4.1%) ( Table 2 ; Figures 2D-F and 3B) . The p-JNK1-3 protein level was significantly reduced in QUC compared to AUC (26.6 ± 6.9% versus 34.1 ± 9.3%, P < 0.0001) and in UC-dysplasia compared to AUC (P < 0.0001) and QUC (P < 0.001). For UC-CRC, we detected significantly decreased p-JNK1-3 expression compared to UC-dysplasia, QUC and AUC (P < 0.0001). p-JNK1-3 is significantly up-regulated in AUC (34.1 ± 9.3%) compared to CD (13.9 ± 6.4%, P < 0.001) and diverticulitis (10.1 ± 6.8%, P < 0.0001). These findings suggest that up-regulation of p-JNK1-3 is linked to colitic inflammation. As shown for p-JNK2, p-JNK1-3 expression was decreased in CD (13.9 ± 6.4%, P = 0.083) and diverticulitis (10.1 ± 6.8%, P < 0.001) compared to control normal colorectal mucosa (19.1 ± 4.1%), AUC (34.1 ± 9.3%, P < 0.001) and to QUC (26.6 ± 6.9%, P<0.001). Furthermore, p-JNK1-3 was unchanged in sporadic adenomas (18.4 ± 7.3%, P=1.000) but decreased in CRC (14.7 ± 10.7%, P = 0.206) compared to control normal colorectal mucosa.
Thus, we detected up-regulation of p-JNK1-3 in AUC as has also been shown in vitro (27) .
γ-H2AX protein expression is lower in colitisassociated cancer compared to sporadic colorectal cancer
We have recently shown that the DNA damage sensor γ-H2AX is a JNK-regulated protein, and that its expression is negatively regulated following repetitive inflammation-associated oxidative stress (27) . Although there was DNA damage, less was signaled through γ-H2AX with the consequence of masked or undetected DNA damage in vitro. Therefore, we asked whether colitis-associated inflammation may cause undetected DNA damage in CRC as measured by reduced γ-H2AX protein expression. Thus, we compared γ-H2AX immunostaining in UC-CRC with that in sporadic CRC (Table 2; Figures 2M-O and  3C ). Protein expression of γ-H2AX was significantly lower in UC-CRC (16.9 ± 10.8%) compared to CRC (33.6 ± 15.7%, P < 0.0003). Furthermore, γ-H2AX expression was significantly increased in CRC compared to all other groups (P < 0.001). Moreover, γ-H2AX expression was increased in AUC (6.6 ± 4.0%, P = 0.258), UC-dysplasia (11.5 ± 6.3%, P < 0.001), sporadic adenoma (10.9 ± 5.3%, P = 0.001) and CRC (33.6 ± 15.7%, P < 0.001) compared to control normal colorectal mucosa (3.7 ± 2.8%), where only a low basal expression could be observed. In contrast, the protein level was virtually the same in QUC (3.3 ± 2.4%, P = 1.000). Expression of γ-H2AX decreased significantly in QUC compared to AUC (6.6 ± 4.4% versus 3.3 ± 2.4, P < 0.0001). Expression of γ-H2AX in diverticulitis (8.1 ± 3.6%) was increased compared to control normal colorectal mucosa (P=0.123) and QUC (P < 0.001) but not to AUC (P = 0.161). In CD, γ-H2AX expression was significantly increased compared to control normal colorectal mucosa (16.5 ± 6.9% versus 3.7 ± 2.8%, P < 0.001), AUC (6.6 ± 4.0%, P < 0.001), and QUC (3.3 ± 2.4%, P < 0.001).
γ-H2AX was not confined to the top of the crypt and the surface epithelium where the mature cells are located, but could also be noticed throughout the whole crypt. On the other hand, the crypt basis with the herein located stem cells showed fewer γ-H2AX-positive cells ( Figure 2M ). In carcinomas, γ-H2AX was less evenly distributed and showed an intense nuclear staining ( Figure 2N and O) .
In summary, we propose that colitis-triggered inflammation may also mask DNA damage in vivo by limiting any increase in γ-HAX2 expression.
p21
WAF1 is down-regulated in the upper-third of crypts during colitis-associated and sporadic colorectal carcinogenesis Notably, p21 WAF1 is a JNK-regulated protein that is down-regulated in UC-related carcinogenesis (5) and in the in vitro UC model (Figure 1) (27,28) . Thus, we analyzed p21 WAF1 expression in the crypts of intestinal tissues (Table 2 ; Figures 2G-I and  3D ). In control normal colorectal mucosa, nuclear staining was confined to the upper-third and the upper part of the middlethird of the crypts as well as the adjacent surface epithelium ( Figure 2G ). In the lower-third of the crypts, we found up-regulated p21 WAF1 in AUC (16.2 ± 13.6%, P < 0.001), QUC (5.6 ± 5.2%, P = 0.959), UC-dysplasia (15.4 ± 13.6%, P < 0.001), as well as in CD (10.3 ± 8.8%, P = 0.185), diverticulitis (6.7 ± 6.6%, P = 0.898), and sporadic adenoma (14.5 ± 16.3%, P = 0.005) compared to control normal colorectal mucosa (3.3 ± 4.4%). In the middle-third, we detected down-regulated p21 WAF1 in UC-dysplasia (29.6 ± 19.3%, P = 0.140), diverticulitis (23.6 ± 21.1%, P = 0.107), and sporadic adenoma (24.3 ± 18.8%, P = 0.145), but up-regulated p21 WAF1 in AUC (49.2 ± 20.7%, P = 0.002) and CD (40.0 ± 11.9%, P = 0.878) compared to control normal colorectal mucosa (35.0 ± 14.0%). In QUC, the p21 WAF1 level was nearly unchanged (37.2 ± 17.0%, P = 0.997). In the upper-third crypt, down-regulated p21 WAF1 was observed in AUC (79.3 ± 14.4%, P = 0.951), QUC (75.4 ± 16.5%, P = 0.288), UC-dysplasia (56.1 ± 17.0%, P < 0.001), diverticulitis (49.5 ± 27.5%, P < 0.001) and sporadic adenoma (52.8 ± 15.4%, P < 0.001) ( Figure 3D ), but up-regulated p21 WAF1 in CD (92.0 ± 9.6%, P = 0.196). In the whole crypt, p21 WAF1 down-regulation was observed in UC-dysplasia (33.7 ± 12.7%, P = 0.004), UC-CRC (22.6 ± 12.8%, P < 0.001), CRC (35.2 ± 11.4%, P = 0.035) and diverticulitis (26.6 ± 14.1%, P < 0.001), while its up-regulation was seen in AUC (48.2 ± 12.0%, P = 0.011) and CD (47.4 ± 7.5%, P = 0.117) compared to control normal colorectal mucosa (40.3 ± 6.8%). This up-regulation was caused by the aforementioned increase in p21 WAF1 expression in the lower crypt parts. In QUC, the p21 WAF1 level was unchanged compared to control normal colorectal mucosa (39.4 ± 9.9%, P = 1.000). In CD, p21 WAF1 was also up-regulated (P = 0.117), but this was statistically not significant. Altogether, we observed p21 WAF1 up-regulation in AUC and its down-regulation in colitis-associated carcinogenesis as has been found in the in vitro model of UC (27, 28) .
Ki67 is up-regulated in the upper-third of the crypt during colitis-associated and sporadic colorectal carcinogenesis
Ki67 expression showed nuclear positivity and was limited to the lower third of the crypt in control normal colorectal mucosa ( Figure 2J ), thereby showing inverse expression compared to p21 WAF1 ( Figure 2G ). In the lower-third crypt, we found downregulated Ki67 in UC-dysplasia (52.8 ± 19.3%, P = 0.561) and sporadic adenoma (41.3 ± 19.8%, P = 0.002), while up-regulated Ki67 was observed in AUC (72.1 ± 13.2%, P = 0.001) compared to control normal colorectal mucosa (58.1 ± 12.9%) ( Table 2 ). Ki67 expression in QUC (P = 0.935), CD (P = 1.000) and diverticulitis (P = 0.999) was similar to control normal colorectal mucosa. In the middle-third, we detected up-regulation of Ki67 in AUC (57.0 ± 16.2%, P < 0.001), QUC (43.0 ± 20.2%, P = 0.054) and UC-dysplasia (49.4 ± 21.0%, P < 0.001) compared to control normal colorectal mucosa (32.0 ± 13.4%). There was a slight increase in Ki67 expression in sporadic adenoma (34.9 ± 19.9%, P = 0.996), a slight decrease in diverticulitis (28.6 ± 21.5%, P = 0.990) and no change in CD (32.8 ± 7.0%, P = 1.000) compared to control normal colorectal mucosa. In the upper-third crypt, an increase of Ki67 was observed in AUC (20.0 ± 14.6%, P < 0.001), QUC (8.3 ± 10.3%, P < 0.354), UC-dysplasia (32.4 ± 21.0%, P < 0.001), CD (13.4 ± 8.8%, P = 0.048), diverticulitis (6.9 ± 10.1%, P = 0.833) and sporadic adenoma (48.2 ± 21.7%, P < 0.001) ( Figure 3E ). On analyzing the whole crypt, we found up-regulated Ki67 in AUC (49.7 ± 9.9%, P < 0.001), QUC (37.6 ± 11.5%, P = 0.060), UC-dysplasia (44.9 ± 13.2%, P < 0.001), UC-CRC (46.8 ± 14.1%, P < 0.001), CD (34.2 ± 5.6%, P = 0.855), sporadic adenoma (41.5 ± 12.8%, P = 0.006) and CRC (54.8 ± 1.7%, P < 0.001) compared to control normal colorectal mucosa (30.7 ± 7.8%). In contrast, Ki67 was equally expressed in diverticulitis and control normal colorectal mucosa.
Overall, we observed increased proliferation in QUC and UC-dysplasia as indicated by up-regulated Ki67, which supports our in vitro data (28) .
Correlation of clinicopathological data
All cases with AUC showed a moderate or strong level of chronic inflammation and so we correlated all cases of AUC (n = 40) against QUC (n = 42). We observed significantly increased expression of all markers in high level of chronic active inflammation in AUC compared to low level of chronic inflammation (p-JNK2: 16.8 ± 4.4% versus 25.4 ± 4.2%, P < 0.0001, p-JNK1-3: 26.6 ± 6.9% versus 34.1 ± 9.3%, P < 0.0001, γ-H2AX: 3.3 ± 2.4% versus 6.6 ± 4.0%, P < 0.0001; Table 3 ). Significantly up-regulated p21 WAF1 was found in the lower-third of the crypt (5.6 ± 5.2% versus 16.2 ± 13.6%, P < 0.0001), the middle-third (37.2 ± 17.0% versus 49.2 ± 20.7%, P = 0.005) and in the whole crypt (39.4 ± 9.9% versus 48.2 ± 12.0%, P = 0.001), but p21 WAF1 was almost unchanged in the upper-third of the crypt (75.4 ± 16.5% versus 79.3 ± 14.4%, P = 0.252, Table 3 ). These results show that an increased level of chronic inflammation causes up-regulated p21 WAF1 expression at the crypts basis in UC. Importantly, we could not show such a correlation for CD and diverticulitis, supporting the idea of an UC-dependent p21 WAF1 regulation. However, we found increased p21 WAF1 expression with an increased level of active inflammation in CD (Z2: P = 0.022, Z3: 0.024, whole crypt: 0.015, Table 3 ).
Zonal and whole crypt Ki67 expression was significantly increased in high level of chronic UC compared to low level of chronic UC (whole crypt, Z1, Z3: P < 0.001, Z2: P = 0.001), but not in chronic CD and diverticulitis (Table 3) . Furthermore, we observed increased p-JNK2 expression in tubulovillous sporadic adenoma compared to tubular sporadic adenoma (17.9 ± 4.4% versus 14.3 ± 3.9%, P = 0.067; Table 3 ), without reaching statistical significance. p-JNK2 expression was up-regulated with increased dedifferentiation of UC-CRC (grade 2: 9.9 ± 5.1%, grade 3: 13.1 ± 3.5%, P = 0.087; Supplementary Table 1, available at Carcinogenesis Online), but was decreased with increased dedifferentiation of CRC (grade 2: 11.9 ± 2.9%, grade 3: 10.2 ± 1.6%, P = 0.224; Supplementary Table 2, available at Carcinogenesis Online). We observed decreased p-JNK1-3 expression in diverticulitis patients with a high degree of active inflammation compared to those with low degree of inflammation (12.8 ± 5.4% versus 7.4 ± 7.2%, P = 0.075; Table 3 ). Moreover, there was a significant increase in γ-H2AX expression in high-grade intraepithelial neoplasia (IEN) compared to low grade IEN for UC-dysplasia (10.1 ± 4.5% versus 13.6 ± 7.9%, P = 0.049; Supplementary Table 1, available at Carcinogenesis Online). There was no statistically significant relation between p-JNK2, p-JNK1-3, γ-H2AX, p21 WAF1 , Ki67 expression and gender, degree of active inflammation in AUC and diverticulitis, proximal or distal localization (except for QUC, Ki67, Z1, P = 0.0035, Table 3 ), depth of invasion (pT), lymph node metastasis (pN), metastasis (pM), tumor staging (UICC), tumor grade (G) and grade of IEN (except for UC-dysplasia, γ-H2AX, P = 0.049) ( Table 3, Supplementary Tables 1 and 2 , available at Carcinogenesis Online). In CD, we observed significant relation between γ-H2AX and chronic inflammation (P < 0.001), location and p21 WAF1 Z2 (P = 0.014) and gender and p21 WAF1 Z1 (P = 0.029).
In summary, we detected a direct link between high level of chronic inflammation in AUC and the up-regulation of p-JNK2, p-JNK1-3, γ-H2AX, p21
WAF1
, and Ki67, which supports the importance of the JNK pathway in vivo.
Discussion
Our recent in vitro studies have highlighted the importance of a switch from JNK-dependent controlled cell cycle arrest in the active phase of UC to JNK-dysregulated cell cycle control in the chronic phase (27, 28) . In this study, we extended our investigations of the proteins of the JNK signaling pathway in resected formalin-fixed, paraffin-embedded tissues by immunohistochemistry.
p-JNK2 up-regulation in AUC and its downregulation in colitis-associated and sporadic colorectal carcinogenesis
Several studies demonstrated a link between JNK activation and intestinal damage (10, 32) . We found increased p-JNK2 expression in AUC, but decreased p-JNK2 expression in QUC, UC-dysplasia, UC-CRC, sporadic adenoma, CRC, CD and diverticulitis (Table 2 ; Figure 3A ), suggesting p-JNK2 as a tumor suppressor in the colitis-inflamed and non-inflamed human colon. In support, JNK2 knockout in mice aggravates DSS-induced colitis (33, 34) , while JNK2 deficiency in liver cells and fibroblasts led to increased proliferation (35) . Our data are in line with the observation that JNK suppresses Ras-stimulated transformation of fibroblasts (36) . On the other hand, Tong et al. (37) identified JNK1 as a tumor suppressor in the intestine and Waetzig et al. (13) found increased activation of JNK in AUC. Furthermore, inhibiting all the different JNK isoforms with the JNK inhibitor SP600125 in rat and mice DSS colitis models protected the colonic tissue from DSS injury (10, 15) . However, the JNK inhibitor can also inhibit other MAPK's (38) . Recently, Liu et al. (12) found that inhibiting necroptosis caused suppression of tumor growth and development by inhibited JNK signaling.
Overall, the question arises how JNK2 is inactivated during colorectal cancer progression. To answer this question, we performed in vitro experiments and found that suppression of JNK activity is realized by caspases, as they execute a non-apoptotic function (27) . In contrast, Sabapathy et al. (35) demonstrated that JNK2 suppresses JNK1. Furthermore, p38alpha is able to inhibit JNK activation in the liver (39) . However, p38 targets both JNK1 and JNK2.
p-JNK1 is up-regulated in QUC and UC-dysplasia
In contrast to p-JNK2, which has been shown to be down-regulated in QUC, UC-dysplasia, UC-CRC, sporadic adenoma, CRC, CD, and diverticulitis, p-JNK1-3 was only decreased in UC-CRC, CRC, CD and diverticulitis (Table 2; Figure 3B ). Importantly, as p-JNK3 is not expressed in the colon, and p-JNK2 was shown to be down-regulated in QUC and UC-dysplasia, we suggest that p-JNK1 is responsible for the observed increased immunostaining with the p-JNK1-3 antibody in QUC and UC-dysplasia. We also observed up-regulation of p-p46 JNK in the quiescent chronic phase in our in vitro model of UC (Figure 1) (28) . Moreover, activated JNK1 seems to be increased in AUC and unchanged in sporadic adenoma (Table 2) . However, it is unclear whether p-JNK1 down-regulation contributes to the observed down-regulation in protein expression in UC-CRC and CRC using the p-JNK1-3 antibody. However, p-JNK2 is definitely down-regulated in UC-CRC and sporadic CRC. 
p21 WAF1 is up-regulated in AUC and down-regulated in colitis-associated and sporadic colorectal carcinogenesis
In this study, we show significant up-regulation of p21 WAF1 in the lower-third of the crypt and in the whole crypt or significantly down-regulated p21 WAF1 in the upper-third and in the whole crypt in colitis-associated colorectal carcinogenesis (Table 2 ; Figure 3D ). This is important in early stages, namely AUC or UC-dysplasia, respectively. In addition, p21
WAF1 up-regulation in the lower-third of the crypt and p21 WAF1 down-regulation in the upper-third and in the whole crypt has also been observed in sporadic colorectal adenoma and cancer. Wong et al. (5) also showed that p21 WAF1 down-regulation is an early event in colitis-associated carcinogenesis. p21 WAF1 down-regulation has also been reported to occur in sporadic colorectal adenomas and carcinomas (40, 41) . In addition, higher p21 WAF1 expression was found in AUC (42, 43) .
In summary, with dysregulation of cell cycle control, decreased p-JNK2 and p-JNK1-3 might correlate with decreased p21 WAF1 expression and increased cell proliferation in colitisassociated colorectal carcinogenesis.
Dysregulated JNK activity in colitis-associated and sporadic colorectal carcinogenesis
As reported in the literature, JNK plays a role in the pathogenesis of human cancer (44) (45) (46) (47) (48) . In AUC, we found increased expression of p-JNK2, p-JNK1-3, p21
WAF1 and γ-H2AX that may induce cell cycle arrest (Table 2 ; Figure 3A-D) . We therefore speculate that JNK activates DNA damage checkpoint control in vivo with up-regulation of p21 WAF1 and γ-H2AX. Induced cell cycle arrest allows repair of DNA damage, but on the other hand, up-regulated Ki67 in AUC indicated increased proliferation of damaged cells, which has also been shown in the in vitro model (27, 28) . Damaged cells with dysregulated JNK activity may override checkpoint control, contributing to enhanced proliferation and regeneration of the colonic tissue (Figure 1 ). p-JNK2 down-regulation has been manifested in QUC, UC-dysplasia, and UC-CRC. Thus, decreased p-JNK2, p21 WAF1 and γ-H2AX but increased Ki67 and p-JNK1-3 may induce proliferation in QUC. In this context, Oka et al. reported an activated DNA damage response during cancer progression in human colorectal carcinoma (49) . As shown in the in vitro model (28), we also observed sinusoidal cell proliferation in vivo as indicated by an increased Ki67 expression in the upper-third crypt and in the whole crypt from normal colorectal mucosa through AUC, QUC, UC-dysplasia to UC-CRC with peaks in AUC and UC-CRC (Table 2; Figure 3E ). UC is a complex barrier disease involving alterations to the Wnt and notch pathway that are linked to Paneth cell and goblet cell function and antimicrobial defense. It should be acknowledged therefore, that the up-and down-regulation of the different markers observed in our studies may be a consequence of a number of mechanisms as yet to be determined. Our results provide the impetus for such mechanistic studies.
Specific effects of colitis-triggered inflammation
Importantly, p-JNK2 and p-JNK1-3 were not up-regulated but down-regulated in CD (P < 0.001, Table 2 ) and diverticulitis compared to AUC (P < 0.001, Table 2 ). As a result, we found down-regulated p21 WAF1 in the middle-third crypt, the upper-third crypt, and the whole crypt in diverticulitis but up-regulated p21 WAF1 in these regions in CD. Instead, in AUC, p21
WAF1 was up-regulated in the lower-third crypt, the middle-third crypt, and in the whole crypt. We therefore postulate that colitis-triggered inflammation activates specifically the JNK pathway, including p21 WAF1 to induce cellular survival via cell cycle arrests in AUC. Moreover, colitis-triggered inflammation induced significant regenerative proliferation as indicated by increased Ki67 expression in every zone, as well as in the whole crypt in AUC. In contrast, we did not find significantly increased Ki67 expression in diverticulitis and CD with exception of significant Ki67 expression only in the upper-third of the crypt (P = 0.048) in CD.
Moreover, expression of p-JNK1-3 was significantly higher than expression of p-JNK2 in UC-dysplasia (P = 0.001) but not in sporadic adenoma (P = 0.866). The difference in the expression of these proteins is of statistical significance (P = 0.045). This increase in p-JNK1-3 expression has also been found in vitro and appears to be triggered by inflammation (28) . Furthermore, γ-H2AX was similarly expressed in UC-dysplasia and sporadic adenoma. However, γ-H2AX was much more increased in CRC than in UC-CRC. This suggests that inflammation may cause undetected DNA damage in UC-CRC as also found in vitro (27) .
Ki67 expression inversely correlates with p21
WAF1 expression
In AUC, we observed an increased p21 WAF1 expression in the whole crypt with a clear shift of the zonally expressed protein from the upper-third of the crypt to the lower-third and middle-third (Table 2 ). In contrast, UC-dysplasia showed decreased p21 WAF1 expression in the whole crypt, which is the consequence of a reversal of zonal p21 WAF1 expression. However, there was no significant correlation of p21 WAF1 expression with the grade of dysplasia. Interestingly, sporadic adenoma showed a similar p21 WAF1 expression pattern with its increase in the lower-third crypt and its decrease in the middle-third and upper-third of the crypt. As cell cycle arrest induced by p21 WAF1 causes a stop in cell proliferation, we found inverse expression of p21 WAF1 and the proliferative marker Ki67 in UC-dysplasia and UC-CRC compared to control normal colorectal mucosa in the lower-third of the crypt and in the whole crypt, respectively (Table 2 ). In the upper-third crypt, we noted inverse expression of p21 WAF1 and Ki67 from normal colorectal mucosa through AUC and QUC to UC-dysplasia compared to control normal colorectal mucosa ( Figure 3D and E). We obtained similar results for sporadic adenoma and CRC.
Conclusion
Overall, the cellular UC model identified molecular mechanisms that also underlie early tumorigenic changes in vivo. Thus, the proposed in vitro model ( Figure 1 ) fits with the in vivo situation. Most importantly: p-JNK2 and p21
WAF1 are up-regulated in the active phase of UC and down-regulated in the quiescent chronic phase in vivo ( Figure 3F ). Based on our results overall, the question arises whether p21 WAF1 is also a JNK-regulated protein in vivo. Thus, future studies should focus on the generation of mechanistic in vivo data through the use of animal models such as JNK2 knockout mice, and the analysis of their p21 WAF1 expression in appropriate tissues.
